Loading clinical trials...
Loading clinical trials...
A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination With Vorinostat for Recurrent or Progressive High- Risk Neuroblastoma Subjects (OPTIMUM TRIAL)
Conditions
Interventions
131I-MIBG
131-MIBG + Vorinostat
Locations
21
United States
Stanford University
Palo Alto, California, United States
UCSF Pediatric Hematology/Oncology
San Francisco, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Nemours Children's Specialty Care
Jacksonville, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Start Date
October 21, 2019
Primary Completion Date
December 1, 2023
Completion Date
April 1, 2025
Last Updated
February 16, 2023
NCT03206060
NCT07541924
NCT07536087
NCT04308330
NCT06190899
NCT07276373
Lead Sponsor
Jubilant DraxImage Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions